Faculty of Economics, Federal University of Bahia, Salvador, Brazil.
Center for Strategic Studies, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
JMIR Public Health Surveill. 2021 Feb 26;7(2):e22483. doi: 10.2196/22483.
The COVID-19 pandemic presents a great public health challenge worldwide, especially given the urgent need to identify effective drugs and develop a vaccine in a short period of time. Globally, several drugs and vaccine candidates are in clinical trials. However, because these drugs and vaccines are still being tested, there is still no definition of which ones will succeed.
This study aimed to assess the opinions of over 1000 virus researchers with knowledge on the prevention and treatment of coronavirus-related human diseases to determine the most promising drug and vaccine candidates to address COVID-19.
We mapped the clinical trials related to COVID-19 registered at ClinicalTrials.gov. These data were used to prepare a survey questionnaire about treatments and vaccine candidates for COVID-19. In May 2020, a global survey was conducted with authors of recent scientific publications indexed in the Web of Science Core Collection related to viruses, severe acute respiratory syndrome coronavirus, coronaviruses, and COVID-19.
Remdesivir, immunoglobulin from cured patients, and plasma were considered to be the most promising treatments in May 2020, while ChAdOx1 and mRNA-1273 were considered to be the most promising vaccine candidates. Almost two-thirds of the respondents (766/1219, 62.8%) believed that vaccines for COVID-19 were likely to be available in the next 18 months. Slightly fewer than 25% (289/1219, 23.7%) believed that a vaccine was feasible, but probably not within 18 months.
The issues addressed in this study are constantly evolving; therefore, the current state of knowledge has changed since the survey was conducted. However, for several months after the survey, the respondents' expectations were in line with recent results related to treatments and vaccine candidates for COVID-19.
COVID-19 大流行在全球范围内带来了巨大的公共卫生挑战，尤其是在短时间内需要确定有效药物和开发疫苗的情况下。全球范围内有几种药物和疫苗候选物正在临床试验中。然而，由于这些药物和疫苗仍在测试中，因此仍不确定哪些药物和疫苗会成功。
本研究旨在评估对预防和治疗与冠状病毒相关人类疾病有了解的 1000 多名病毒研究人员的意见，以确定最有前途的药物和疫苗候选物来解决 COVID-19 问题。
我们对在 ClinicalTrials.gov 上注册的与 COVID-19 相关的临床试验进行了映射。这些数据用于准备有关 COVID-19 治疗和疫苗候选物的调查问卷调查。2020 年 5 月，对在 Web of Science 核心合集索引的与病毒、严重急性呼吸综合征冠状病毒、冠状病毒和 COVID-19 相关的近期科学出版物的作者进行了一项全球性调查。
瑞德西韦、康复患者的免疫球蛋白和血浆被认为是 2020 年 5 月最有前途的治疗方法，而 ChAdOx1 和 mRNA-1273 被认为是最有前途的疫苗候选物。近三分之二的受访者（766/1219，62.8%）认为 COVID-19 疫苗可能在未来 18 个月内可用。略低于 25%（289/1219，23.7%）的人认为疫苗是可行的，但可能不在 18 个月内。
本研究中涉及的问题在不断发展；因此，自调查以来，当前的知识状况已经发生了变化。然而，在调查进行后的几个月里，受访者的期望与 COVID-19 治疗和疫苗候选物的最新结果一致。
Zotero 插件
